Compare Immunovant Inc. Common Stock (IMVT) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs iShares MSCI China ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while iShares MSCI China ETF trades at $51.85 (market cap $6.00B). The key difference: Immunovant Inc. Common Stock and iShares MSCI China ETF are close in size by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and iShares MSCI China ETF for 63 Days on average.
| IMVT | MCHI | |
|---|---|---|
Market Cap | $6.62B | $6.00B |
Volume | 1,131,364 | 1,917,899 |
Sector | Health | Broad Market / Factor |
52-Week High | $44.96 | $65.59 |
52-Week Low | $17.03 | $50.48 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MCHI trades at $51.64, down 1.11% with a bearish technical signal from moving averages and oscillators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support levels cluster around $51-52 with resistance at $52, indicating consolidation near current levels amid mixed market sentiment.
The outlook remains cautious due to China's macroeconomic pressures and global trade friction, though historical discount to US indices presents potential value. Key risks include export restrictions, protectionism threats, and domestic consumption weakness. Institutional activity shows mixed positioning with recent acquisitions offset by reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
